首页 > 最新文献

Tuberculosis and Respiratory Diseases最新文献

英文 中文
Negative Conversion of Polymerase Chain Reaction and Clinical Outcomes according to the SARS-CoV-2 Variant in Critically Ill Patients with COVID-19. COVID-19危重症患者聚合酶链反应阴性转化及SARS-CoV-2变异的临床结果
IF 2.9 Q2 RESPIRATORY SYSTEM Pub Date : 2023-04-01 DOI: 10.4046/trd.2022.0151
Tae Hun Kim, Eunjeong Ji, Myung Jin Song, Sung Yoon Lim, Yeon Joo Lee, Young-Jae Cho

Background: Coronavirus disease 2019 (COVID-19) is an ongoing global public health threat and different variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been identified. This study aimed to analyse the factors associated with negative conversion of polymerase chain reaction (PCR) and prognosis in critically ill patients according to the SARS-CoV-2 variant.

Methods: This study retrospectively analysed 259 critically ill patients with COVID-19 who were admitted to the intensive care unit of a tertiary medical center between January 2020 and May 2022. The Charlson comorbidity index (CCI) was used to evaluate comorbidity, and a negative PCR test result within 2 weeks was used to define negative PCR conversion. The cases were divided into the following three variant groups, according to the documented variant of SARS-CoV-2 at the time of diagnosis: non-Delta (January 20, 2020-July 6, 2021), Delta (July 7, 2021- January 1, 2022), and Omicron (January 30, 2022-April 24, 2022).

Results: The mean age of the 259 patients was 67.1 years and 93 (35.9%) patients were female. Fifty (19.3%) patients were smokers, and 50 (19.3%) patients were vaccinated. The CCI (hazard ratio [HR], 1.555; p<0.001), vaccination (HR, 0.492; p=0.033), and Delta variant (HR, 2.469; p=0.002) were significant factors for in-hospital mortality. The Delta variant (odds ratio, 0.288; p=0.003) was associated with fewer negative PCR conversion; however, vaccination (p=0.163) and remdesivir (p=0.124) treatments did not.

Conclusion: The Delta variant of SARS-CoV-2 is associated with lower survival and negative PCR conversion. Contrary to expectations, vaccination and remdesivir may not affect negative PCR conversion in critically ill patients with COVID-19.

背景:冠状病毒病2019 (COVID-19)是一种持续的全球公共卫生威胁,严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)的不同变体已经被发现。本研究旨在分析SARS-CoV-2亚型重症患者聚合酶链反应(PCR)阴性转化及预后的相关因素。方法:本研究回顾性分析2020年1月至2022年5月在某三级医疗中心重症监护室收治的259例COVID-19危重患者。采用Charlson合并症指数(CCI)评价合并症,以2周内PCR阴性检测结果判定PCR转化为阴性。根据诊断时记录的SARS-CoV-2变体,将病例分为以下三个变体组:非Delta(2020年1月20日- 2021年7月6日)、Delta(2021年7月7日- 2022年1月1日)和Omicron(2022年1月30日- 2022年4月24日)。结果:259例患者平均年龄67.1岁,女性93例(35.9%)。吸烟50例(19.3%),接种疫苗50例(19.3%)。CCI(风险比[HR], 1.555;p<0.001),接种疫苗(HR, 0.492;p=0.033), Delta变异(HR, 2.469;P =0.002)是住院死亡率的显著因素。δ变异(优势比,0.288;p=0.003)与较少的PCR阴性转化相关;然而,接种疫苗(p=0.163)和瑞德西韦(p=0.124)治疗则没有效果。结论:δ型SARS-CoV-2与低生存率和PCR阴性转化相关。与预期相反,疫苗接种和瑞德西韦可能不会影响COVID-19危重患者的PCR阴性转化。
{"title":"Negative Conversion of Polymerase Chain Reaction and Clinical Outcomes according to the SARS-CoV-2 Variant in Critically Ill Patients with COVID-19.","authors":"Tae Hun Kim,&nbsp;Eunjeong Ji,&nbsp;Myung Jin Song,&nbsp;Sung Yoon Lim,&nbsp;Yeon Joo Lee,&nbsp;Young-Jae Cho","doi":"10.4046/trd.2022.0151","DOIUrl":"https://doi.org/10.4046/trd.2022.0151","url":null,"abstract":"<p><strong>Background: </strong>Coronavirus disease 2019 (COVID-19) is an ongoing global public health threat and different variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been identified. This study aimed to analyse the factors associated with negative conversion of polymerase chain reaction (PCR) and prognosis in critically ill patients according to the SARS-CoV-2 variant.</p><p><strong>Methods: </strong>This study retrospectively analysed 259 critically ill patients with COVID-19 who were admitted to the intensive care unit of a tertiary medical center between January 2020 and May 2022. The Charlson comorbidity index (CCI) was used to evaluate comorbidity, and a negative PCR test result within 2 weeks was used to define negative PCR conversion. The cases were divided into the following three variant groups, according to the documented variant of SARS-CoV-2 at the time of diagnosis: non-Delta (January 20, 2020-July 6, 2021), Delta (July 7, 2021- January 1, 2022), and Omicron (January 30, 2022-April 24, 2022).</p><p><strong>Results: </strong>The mean age of the 259 patients was 67.1 years and 93 (35.9%) patients were female. Fifty (19.3%) patients were smokers, and 50 (19.3%) patients were vaccinated. The CCI (hazard ratio [HR], 1.555; p&lt;0.001), vaccination (HR, 0.492; p=0.033), and Delta variant (HR, 2.469; p=0.002) were significant factors for in-hospital mortality. The Delta variant (odds ratio, 0.288; p=0.003) was associated with fewer negative PCR conversion; however, vaccination (p=0.163) and remdesivir (p=0.124) treatments did not.</p><p><strong>Conclusion: </strong>The Delta variant of SARS-CoV-2 is associated with lower survival and negative PCR conversion. Contrary to expectations, vaccination and remdesivir may not affect negative PCR conversion in critically ill patients with COVID-19.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":"86 2","pages":"142-149"},"PeriodicalIF":2.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fe/f0/trd-2022-0151.PMC10073602.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9262178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Alcohol Consumption on Quality of Life, Depressive Mood and Metabolic Syndrome in Obstructive Lung Disease Patients: Analysis of Data from Korean National Health and Nutrition Examination Survey from 2014 and 2016. 酒精消费对阻塞性肺疾病患者生活质量、抑郁情绪和代谢综合征的影响:2014年和2016年韩国国民健康与营养调查数据分析
IF 2.9 Q2 RESPIRATORY SYSTEM Pub Date : 2023-04-01 DOI: 10.4046/trd.2022.0107
I Re Heo, Tae Hoon Kim, Jong Hwan Jeong, Manbong Heo, Sun Mi Ju, Jung-Wan Yoo, Seung Jun Lee, Yu Ji Cho, Yi Yeong Jeong, Jong Deog Lee, Ho Cheol Kim

Background: The objective of this study was to investigate whether alcohol consumption might affect the quality of life (QOL), depressive mood, and metabolic syndrome in patients with obstructive lung disease (OLD).

Methods: Data were obtained from the Korean National Health and Nutrition Examination Survey from 2014 and 2016. OLD was defined as spirometry of forced expiratory volume in 1 second/forced vital capacity <0.7 in those aged more than 40 years. QOL was evaluated using the European Quality of Life Questionnaire-5D (EQ-5D) index. Patient Health Questionnaire-9 (PHQ-9) was used to assess the severity of depressive mood. Alcohol consumption was based on a history of alcohol ingestion during the previous month.

Results: A total of 984 participants with OLD (695 males, 289 females, age 65.8±9.7 years) were enrolled. The EQ-5D index was significantly higher in alcohol drinkers (n=525) than in non-alcohol drinkers (n=459) (0.94±0.11 vs. 0.91±0.13, p=0.002). PHQ- 9 scores were considerably lower in alcohol drinkers than in non-alcohol drinkers (2.15±3.57 vs. 2.78±4.13, p=0.013). However, multiple logistic regression analysis showed that alcohol consumption was not associated with EQ-5D index or PHQ-9 score. Body mass index ≥25 kg/m2, triglyceride ≥150 mg/dL, high-density lipoprotein <40 mg/dL in men and <50 mg/dL in women, and blood pressure ≥130/85 mm Hg were significantly more common in alcohol drinkers than in non-alcohol drinkers (all p<0.05).

Conclusion: Alcohol consumption did not change the QOL or depressive mood of OLD patients. However, metabolic syndrome-related factors were more common in alcohol drinkers than in non-alcohol drinkers.

背景:本研究的目的是探讨饮酒是否会影响阻塞性肺疾病(OLD)患者的生活质量(QOL)、抑郁情绪和代谢综合征。方法:数据来源于2014年和2016年韩国国民健康与营养检查调查。年龄在40岁以上的患者,以1秒用力呼气量/用力肺活量<0.7的肺活量来定义OLD。QOL采用欧洲生活质量问卷- 5d (EQ-5D)指数进行评估。采用患者健康问卷-9 (PHQ-9)评估抑郁情绪的严重程度。饮酒量是基于前一个月的酒精摄入史。结果:共纳入984例老年患者(男性695例,女性289例,年龄65.8±9.7岁)。饮酒者(n=525)的EQ-5D指数显著高于非饮酒者(n=459)(0.94±0.11比0.91±0.13,p=0.002)。饮酒者的PHQ- 9得分明显低于非饮酒者(2.15±3.57比2.78±4.13,p=0.013)。然而,多元logistic回归分析显示,饮酒与EQ-5D指数或PHQ-9评分无关。体重指数≥25kg /m2,甘油三酯≥150mg /dL,男性高密度脂蛋白≥40mg /dL,女性≥50mg /dL,血压≥130/ 85mmhg在饮酒者中比在非饮酒者中更为常见(均为0.05)。结论:饮酒未改变老年患者的生活质量和抑郁情绪。然而,代谢综合征相关因素在饮酒者中比在非饮酒者中更常见。
{"title":"Impact of Alcohol Consumption on Quality of Life, Depressive Mood and Metabolic Syndrome in Obstructive Lung Disease Patients: Analysis of Data from Korean National Health and Nutrition Examination Survey from 2014 and 2016.","authors":"I Re Heo,&nbsp;Tae Hoon Kim,&nbsp;Jong Hwan Jeong,&nbsp;Manbong Heo,&nbsp;Sun Mi Ju,&nbsp;Jung-Wan Yoo,&nbsp;Seung Jun Lee,&nbsp;Yu Ji Cho,&nbsp;Yi Yeong Jeong,&nbsp;Jong Deog Lee,&nbsp;Ho Cheol Kim","doi":"10.4046/trd.2022.0107","DOIUrl":"https://doi.org/10.4046/trd.2022.0107","url":null,"abstract":"<p><strong>Background: </strong>The objective of this study was to investigate whether alcohol consumption might affect the quality of life (QOL), depressive mood, and metabolic syndrome in patients with obstructive lung disease (OLD).</p><p><strong>Methods: </strong>Data were obtained from the Korean National Health and Nutrition Examination Survey from 2014 and 2016. OLD was defined as spirometry of forced expiratory volume in 1 second/forced vital capacity &lt;0.7 in those aged more than 40 years. QOL was evaluated using the European Quality of Life Questionnaire-5D (EQ-5D) index. Patient Health Questionnaire-9 (PHQ-9) was used to assess the severity of depressive mood. Alcohol consumption was based on a history of alcohol ingestion during the previous month.</p><p><strong>Results: </strong>A total of 984 participants with OLD (695 males, 289 females, age 65.8±9.7 years) were enrolled. The EQ-5D index was significantly higher in alcohol drinkers (n=525) than in non-alcohol drinkers (n=459) (0.94±0.11 vs. 0.91±0.13, p=0.002). PHQ- 9 scores were considerably lower in alcohol drinkers than in non-alcohol drinkers (2.15±3.57 vs. 2.78±4.13, p=0.013). However, multiple logistic regression analysis showed that alcohol consumption was not associated with EQ-5D index or PHQ-9 score. Body mass index ≥25 kg/m2, triglyceride ≥150 mg/dL, high-density lipoprotein &lt;40 mg/dL in men and &lt;50 mg/dL in women, and blood pressure ≥130/85 mm Hg were significantly more common in alcohol drinkers than in non-alcohol drinkers (all p&lt;0.05).</p><p><strong>Conclusion: </strong>Alcohol consumption did not change the QOL or depressive mood of OLD patients. However, metabolic syndrome-related factors were more common in alcohol drinkers than in non-alcohol drinkers.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":"86 2","pages":"111-119"},"PeriodicalIF":2.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ad/f2/trd-2022-0107.PMC10073609.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9262714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Improving Tuberculosis Medication Adherence: The Potential of Integrating Digital Technology and Health Belief Model. 提高结核病药物依从性:整合数字技术与健康信念模型的潜力。
IF 2.9 Q2 RESPIRATORY SYSTEM Pub Date : 2023-04-01 DOI: 10.4046/trd.2022.0148
Mohd Fazeli Sazali, Syed Sharizman Syed Abdul Rahim, Ahmad Hazim Mohammad, Fairrul Kadir, Alvin Oliver Payus, Richard Avoi, Mohammad Saffree Jeffree, Azizan Omar, Mohd Yusof Ibrahim, Azman Atil, Nooralisa Mohd Tuah, Rahmat Dapari, Meryl Grace Lansing, Ahmad Asyraf Abdul Rahim, Zahir Izuan Azhar

Tuberculosis (TB) is a significant public health concern. Globally, TB is among the top 10 and the leading cause of death due to a single infectious agent. Providing standard anti-TB therapy for at least 6 months is recommended as one of the crucial strategies to control the TB epidemic. However, the long duration of TB treatment raised the issue of non-adherence. Non-adherence to TB therapy could negatively affect clinical and public health outcomes. Thus, directly observed therapy (DOT) has been introduced as a standard strategy to improve anti-TB medication adherence. Nonetheless, the DOT approach has been criticized due to inconvenience, stigma, reduced economic productivity, and reduced quality of life, which ultimately could complicate adherence issues. Apart from that, its effectiveness in improving anti-TB adherence is debatable. Therefore, digital technology could be an essential tool to enhance the implementation of DOT. Incorporating the health belief model (HBM) into digital technology can further increase its effectiveness in changing behavior and improving medication adherence. This article aimed to review the latest evidence regarding TB medication non-adherence, its associated factors, DOT's efficacy and its alternatives, and the use of digital technology and HBM in improving medication adherence. This paper used the narrative review methodology to analyze related articles to address the study objectives. Conventional DOT has several disadvantages in TB management. Integrating HBM in digital technology development is potentially effective in improving medication adherence. Digital technology provides an opportunity to improve medication adherence to overcome various issues related to DOT implementation.

结核病是一个重大的公共卫生问题。在全球范围内,结核病是由单一传染病引起的十大死亡原因之一,也是导致死亡的主要原因。建议提供至少6个月的标准抗结核治疗,作为控制结核病流行的关键战略之一。然而,结核病治疗的长期持续引发了不依从的问题。不坚持结核病治疗可能对临床和公共卫生结果产生负面影响。因此,直接观察疗法(DOT)已被引入作为提高抗结核药物依从性的标准策略。尽管如此,由于不便、耻辱、降低经济生产力和降低生活质量,DOT方法一直受到批评,最终可能使依从性问题复杂化。除此之外,它在提高抗结核依从性方面的有效性值得商榷。因此,数字技术可以成为加强DOT实施的重要工具。将健康信念模型(HBM)与数字技术相结合,可以进一步提高其在改变行为和改善药物依从性方面的有效性。本文旨在综述有关结核病药物依从性、相关因素、DOT的疗效和替代方法,以及数字技术和HBM在改善药物依从性方面的应用的最新证据。本文采用叙事回顾的方法对相关文献进行分析,以达到研究目的。传统的DOT在结核病管理中有几个缺点。将HBM整合到数字技术开发中可能有效地提高药物依从性。数字技术提供了改善药物依从性的机会,以克服与DOT实施相关的各种问题。
{"title":"Improving Tuberculosis Medication Adherence: The Potential of Integrating Digital Technology and Health Belief Model.","authors":"Mohd Fazeli Sazali,&nbsp;Syed Sharizman Syed Abdul Rahim,&nbsp;Ahmad Hazim Mohammad,&nbsp;Fairrul Kadir,&nbsp;Alvin Oliver Payus,&nbsp;Richard Avoi,&nbsp;Mohammad Saffree Jeffree,&nbsp;Azizan Omar,&nbsp;Mohd Yusof Ibrahim,&nbsp;Azman Atil,&nbsp;Nooralisa Mohd Tuah,&nbsp;Rahmat Dapari,&nbsp;Meryl Grace Lansing,&nbsp;Ahmad Asyraf Abdul Rahim,&nbsp;Zahir Izuan Azhar","doi":"10.4046/trd.2022.0148","DOIUrl":"https://doi.org/10.4046/trd.2022.0148","url":null,"abstract":"<p><p>Tuberculosis (TB) is a significant public health concern. Globally, TB is among the top 10 and the leading cause of death due to a single infectious agent. Providing standard anti-TB therapy for at least 6 months is recommended as one of the crucial strategies to control the TB epidemic. However, the long duration of TB treatment raised the issue of non-adherence. Non-adherence to TB therapy could negatively affect clinical and public health outcomes. Thus, directly observed therapy (DOT) has been introduced as a standard strategy to improve anti-TB medication adherence. Nonetheless, the DOT approach has been criticized due to inconvenience, stigma, reduced economic productivity, and reduced quality of life, which ultimately could complicate adherence issues. Apart from that, its effectiveness in improving anti-TB adherence is debatable. Therefore, digital technology could be an essential tool to enhance the implementation of DOT. Incorporating the health belief model (HBM) into digital technology can further increase its effectiveness in changing behavior and improving medication adherence. This article aimed to review the latest evidence regarding TB medication non-adherence, its associated factors, DOT's efficacy and its alternatives, and the use of digital technology and HBM in improving medication adherence. This paper used the narrative review methodology to analyze related articles to address the study objectives. Conventional DOT has several disadvantages in TB management. Integrating HBM in digital technology development is potentially effective in improving medication adherence. Digital technology provides an opportunity to improve medication adherence to overcome various issues related to DOT implementation.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":"86 2","pages":"82-93"},"PeriodicalIF":2.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/27/52/trd-2022-0148.PMC10073608.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9320916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
The Importance of Early Chronic Obstructive Pulmonary Disease: A Lecture from 2022 Asian Pacific Society of Respirology. 早期慢性阻塞性肺疾病的重要性:2022年亚太呼吸学会讲座。
IF 2.9 Q2 RESPIRATORY SYSTEM Pub Date : 2023-04-01 DOI: 10.4046/trd.2023.0005
Don D Sin

Chronic obstructive pulmonary disease (COPD) affects close to 400 million people worldwide. COPD is characterized by significant airflow limitation on spirometry. Most patients with COPD are diagnosed in their fifth or sixth decades of life. However, the disease begins much earlier. By the time airflow limitation is detected on spirometry, patients with COPD have lost close to 50% of their small airways. Thus, identification of patients with early COPD, defined as persons with preserved spirometry, who demonstrate pathologic or functional hallmarks of COPD, is essential for disease modification and ultimately disease elimination. This paper provides an up-to-date overview of the current case definition of early COPD, its importance, the novel technologies required for its detection in young adults and future directions in therapeutics for treatment.

慢性阻塞性肺疾病(COPD)影响全世界近4亿人。COPD的特点是肺活量测定的气流明显受限。大多数慢性阻塞性肺病患者在五、六十岁时被诊断出来。然而,这种疾病的发病时间要早得多。当肺活量测定法检测到气流受限时,COPD患者已经失去了近50%的小气道。因此,早期COPD患者(定义为肺活量测定保持不变的患者,其表现出COPD的病理或功能特征)的识别对于疾病改善和最终消除疾病至关重要。本文提供了当前早期COPD病例定义的最新概述,其重要性,在年轻人中检测其所需的新技术以及治疗方法的未来方向。
{"title":"The Importance of Early Chronic Obstructive Pulmonary Disease: A Lecture from 2022 Asian Pacific Society of Respirology.","authors":"Don D Sin","doi":"10.4046/trd.2023.0005","DOIUrl":"https://doi.org/10.4046/trd.2023.0005","url":null,"abstract":"<p><p>Chronic obstructive pulmonary disease (COPD) affects close to 400 million people worldwide. COPD is characterized by significant airflow limitation on spirometry. Most patients with COPD are diagnosed in their fifth or sixth decades of life. However, the disease begins much earlier. By the time airflow limitation is detected on spirometry, patients with COPD have lost close to 50% of their small airways. Thus, identification of patients with early COPD, defined as persons with preserved spirometry, who demonstrate pathologic or functional hallmarks of COPD, is essential for disease modification and ultimately disease elimination. This paper provides an up-to-date overview of the current case definition of early COPD, its importance, the novel technologies required for its detection in young adults and future directions in therapeutics for treatment.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":"86 2","pages":"71-81"},"PeriodicalIF":2.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/74/a0/trd-2023-0005.PMC10073605.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9269710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Review of Internet of Things-Based Artificial Intelligence Analysis Method through Real-Time Indoor Air Quality and Health Effect Monitoring: Focusing on Indoor Air Pollution That Are Harmful to the Respiratory Organ. 基于物联网的室内空气质量与健康影响实时监测人工智能分析方法综述:关注对呼吸器官有害的室内空气污染。
IF 2.5 Q2 RESPIRATORY SYSTEM Pub Date : 2023-01-01 Epub Date: 2022-10-26 DOI: 10.4046/trd.2022.0087
EunMi Mun, Jaehyuk Cho

Everyone is aware that air and environmental pollutants are harmful to health. Among them, indoor air quality directly affects physical health, such as respiratory rather than outdoor air. However, studies that have examined the correlation between environmental and health information have been conducted with public data targeting large cohorts, and studies with real-time data analysis are insufficient. Therefore, this research explores the research with an indoor air quality monitoring (AQM) system based on developing environmental detection sensors and the internet of things to collect, monitor, and analyze environmental and health data from various data sources in real-time. It explores the usage of wearable devices for health monitoring systems. In addition, the availability of big data and artificial intelligence analysis and prediction has increased, investigating algorithmic studies for accurate prediction of hazardous environments and health impacts. Regarding health effects, techniques to prevent respiratory and related diseases were reviewed.

众所周知,空气和环境污染物对健康有害。其中,与室外空气相比,室内空气质量直接影响呼吸道等身体健康。然而,研究环境与健康信息之间相关性的研究都是针对大型群组的公共数据进行的,实时数据分析的研究并不充分。因此,本研究探讨了基于开发环境检测传感器和物联网的室内空气质量监测(AQM)系统的研究,以实时收集、监测和分析来自各种数据源的环境和健康数据。研究还探讨了可穿戴设备在健康监测系统中的应用。此外,大数据和人工智能分析与预测的可用性也在增加,调查了准确预测危险环境和健康影响的算法研究。在健康影响方面,审查了预防呼吸道疾病和相关疾病的技术。
{"title":"Review of Internet of Things-Based Artificial Intelligence Analysis Method through Real-Time Indoor Air Quality and Health Effect Monitoring: Focusing on Indoor Air Pollution That Are Harmful to the Respiratory Organ.","authors":"EunMi Mun, Jaehyuk Cho","doi":"10.4046/trd.2022.0087","DOIUrl":"10.4046/trd.2022.0087","url":null,"abstract":"<p><p>Everyone is aware that air and environmental pollutants are harmful to health. Among them, indoor air quality directly affects physical health, such as respiratory rather than outdoor air. However, studies that have examined the correlation between environmental and health information have been conducted with public data targeting large cohorts, and studies with real-time data analysis are insufficient. Therefore, this research explores the research with an indoor air quality monitoring (AQM) system based on developing environmental detection sensors and the internet of things to collect, monitor, and analyze environmental and health data from various data sources in real-time. It explores the usage of wearable devices for health monitoring systems. In addition, the availability of big data and artificial intelligence analysis and prediction has increased, investigating algorithmic studies for accurate prediction of hazardous environments and health impacts. Regarding health effects, techniques to prevent respiratory and related diseases were reviewed.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":"86 1","pages":"23-32"},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e4/26/trd-2022-0087.PMC9816487.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10867778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Definition of Chronic Obstructive Pulmonary Disease Exacerbation: The Essentials of the Rome Proposal. 慢性阻塞性肺疾病加重的定义:罗马建议要点
IF 2.9 Q2 RESPIRATORY SYSTEM Pub Date : 2023-01-01 DOI: 10.4046/trd.2022.0119
Yeon-Mok Oh
It is identical to the Creative Commons Attribution NonCommercial License (http:// creativecommons.org/licenses/ by-nc/4.0/). Last year, a group of experts on chronic obstructive pulmonary disease (COPD) proposed an updated definition of COPD exacerbation. They reached a consensus on the new definition using a modified Delphi method and named it ‘the Rome Proposal’ (Table 1). As a correct definition of COPD exacerbation is necessary not only for clinical practice but also for healthcare decisions, the Rome Proposal was designed to overcome the shortcomings of the current definition of COPD exacerbation documented by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy. One of the shortcomings of the GOLD definition is that it relies only on subjective symptoms, which can be mimicked by pneumonia, heart failure, or pulmonary thromboembolism. In contrast, in the Rome Proposal, the experts suggested objective measurements of respiratory rate, heart rate, serum C-reactive protein, pulse oximetry, and arterial blood gas in addition to the symptoms. The Rome Proposal also suggests the evaluation of differential diagnosis and etiologic testing for airway insult and removes the term, “additional therapy” from the definition of COPD exacerbation. This is because an additional therapy may differ across COPD patients due to its availability and the preference of patients or physicians upon COPD exacerbation. However, a good definition should be concise, with the exclusion of non-essential components, and must be composed of two parts—genus (category of concept) and differentia (differentiating characteristics). A good definition of COPD exacerbation is fundamental for precise communication among healthcare professionals, patients, medical students, and even the general public. Considering the com-
{"title":"Definition of Chronic Obstructive Pulmonary Disease Exacerbation: The Essentials of the Rome Proposal.","authors":"Yeon-Mok Oh","doi":"10.4046/trd.2022.0119","DOIUrl":"https://doi.org/10.4046/trd.2022.0119","url":null,"abstract":"It is identical to the Creative Commons Attribution NonCommercial License (http:// creativecommons.org/licenses/ by-nc/4.0/). Last year, a group of experts on chronic obstructive pulmonary disease (COPD) proposed an updated definition of COPD exacerbation. They reached a consensus on the new definition using a modified Delphi method and named it ‘the Rome Proposal’ (Table 1). As a correct definition of COPD exacerbation is necessary not only for clinical practice but also for healthcare decisions, the Rome Proposal was designed to overcome the shortcomings of the current definition of COPD exacerbation documented by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy. One of the shortcomings of the GOLD definition is that it relies only on subjective symptoms, which can be mimicked by pneumonia, heart failure, or pulmonary thromboembolism. In contrast, in the Rome Proposal, the experts suggested objective measurements of respiratory rate, heart rate, serum C-reactive protein, pulse oximetry, and arterial blood gas in addition to the symptoms. The Rome Proposal also suggests the evaluation of differential diagnosis and etiologic testing for airway insult and removes the term, “additional therapy” from the definition of COPD exacerbation. This is because an additional therapy may differ across COPD patients due to its availability and the preference of patients or physicians upon COPD exacerbation. However, a good definition should be concise, with the exclusion of non-essential components, and must be composed of two parts—genus (category of concept) and differentia (differentiating characteristics). A good definition of COPD exacerbation is fundamental for precise communication among healthcare professionals, patients, medical students, and even the general public. Considering the com-","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":"86 1","pages":"61-62"},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4c/2e/trd-2022-0119.PMC9816486.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10868330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Early Use of High Flow Nasal Cannula in Postextubation Period: Can It Reduce Reintubation Rate? 在拔管后早期使用高流量鼻套管:能降低再插管率吗?
IF 2.9 Q2 RESPIRATORY SYSTEM Pub Date : 2023-01-01 DOI: 10.4046/trd.2022.0113
Prosenjit Mukherjee, Mohanchandra Mandal, Antonio M Esquinas
Prosenjit Mukherjee, Mohanchandra Mandal, Antonio M. Esquinas. Authors: 1. Dr.Prosenjit Mukherjee (MD) Associate Professor, Department of Anaesthesiology, Institute of Post Graduate Medical Education & Research, Kolkata, West Bengal, India. Email: docposhu@gmail.com Orcid Id: 0000-0002-6228-3769 2. Dr.Mohanchandra Mandal (MD) Professor, Department of Anaesthesiology Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India. Email: drmcmandal@gmail.com Orcid ID: 0000-0003-4183-993X 3. Dr.Antonio M. Esquinas(MD, PhD, FCCP, FNIV, FAARC) Critical Care Specialist and Staff Physician, Intensive Care Unit, Hospital Morales, Meseguer, Murcia, Spain. Email:antmesquinas@gmail.com Orcid ID: 0000-0003-0571-2050
{"title":"Early Use of High Flow Nasal Cannula in Postextubation Period: Can It Reduce Reintubation Rate?","authors":"Prosenjit Mukherjee,&nbsp;Mohanchandra Mandal,&nbsp;Antonio M Esquinas","doi":"10.4046/trd.2022.0113","DOIUrl":"https://doi.org/10.4046/trd.2022.0113","url":null,"abstract":"Prosenjit Mukherjee, Mohanchandra Mandal, Antonio M. Esquinas. Authors: 1. Dr.Prosenjit Mukherjee (MD) Associate Professor, Department of Anaesthesiology, Institute of Post Graduate Medical Education & Research, Kolkata, West Bengal, India. Email: docposhu@gmail.com Orcid Id: 0000-0002-6228-3769 2. Dr.Mohanchandra Mandal (MD) Professor, Department of Anaesthesiology Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India. Email: drmcmandal@gmail.com Orcid ID: 0000-0003-4183-993X 3. Dr.Antonio M. Esquinas(MD, PhD, FCCP, FNIV, FAARC) Critical Care Specialist and Staff Physician, Intensive Care Unit, Hospital Morales, Meseguer, Murcia, Spain. Email:antmesquinas@gmail.com Orcid ID: 0000-0003-0571-2050","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":"86 1","pages":"63-64"},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/eb/d5/trd-2022-0113.PMC9816493.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10510615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early Use of High-Flow Nasal Cannula in Postextubation Period: Can It Reduce Reintubation Rate? Authors' Reply. 在拔管后早期使用高流量鼻套管:能降低再插管率吗?作者的回答。
IF 2.9 Q2 RESPIRATORY SYSTEM Pub Date : 2023-01-01 DOI: 10.4046/trd.2022.0161
Jae Kyeom Sim, Young Seok Lee
Address for correspondence Young Seok Lee, M.D., Ph.D. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, 148 Gurodong-ro, Guro-gu, Seoul 08308, Republic of Korea Phone 82-2-2626-3256 Fax 82-2-2626-1166 E-mail avonlea76@korea.ac.kr Received Dec. 8, 2022 Revised Dec. 9, 2022 Accepted Dec. 9, 2022 Published online Dec. 12, 2022
{"title":"Early Use of High-Flow Nasal Cannula in Postextubation Period: Can It Reduce Reintubation Rate? Authors' Reply.","authors":"Jae Kyeom Sim,&nbsp;Young Seok Lee","doi":"10.4046/trd.2022.0161","DOIUrl":"https://doi.org/10.4046/trd.2022.0161","url":null,"abstract":"Address for correspondence Young Seok Lee, M.D., Ph.D. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, 148 Gurodong-ro, Guro-gu, Seoul 08308, Republic of Korea Phone 82-2-2626-3256 Fax 82-2-2626-1166 E-mail avonlea76@korea.ac.kr Received Dec. 8, 2022 Revised Dec. 9, 2022 Accepted Dec. 9, 2022 Published online Dec. 12, 2022","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":"86 1","pages":"65-66"},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f8/e5/trd-2022-0161.PMC9816485.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10509613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Targeted Therapy for Non-Small Cell Lung Cancer. 非小细胞肺癌的新型靶向疗法。
IF 2.5 Q2 RESPIRATORY SYSTEM Pub Date : 2023-01-01 Epub Date: 2022-10-05 DOI: 10.4046/trd.2022.0066
Eun Ki Chung, Seung Hyun Yong, Eun Hye Lee, Eun Young Kim, Yoon Soo Chang, Sang Hoon Lee

Lung cancer ranks first in cancer mortality in Korea and cancer incidence in Korean men. More than half of Korean lung cancer patients undergo chemotherapy, including adjuvant therapy. Cytotoxic agents, targeted therapy, and immune checkpoint inhibitors are used in chemotherapy according to the biopsy and genetic test results. Among chemotherapy, the one that has developed rapidly is targeted therapy. The National Comprehensive Cancer Network (NCCN) guidelines have been updated recently for targeted therapy of multiple gene mutations, and targeted therapy is used not only for chemotherapy but also for adjuvant therapy. While previously targeted therapies have been developed for common genetic mutations, recently targeted therapies have been developed to overcome uncommon mutations or drug resistance that have occurred since previous targeted therapy. Therefore, this study describes recent, rapidly developing targeted therapies.

肺癌在韩国癌症死亡率和韩国男性癌症发病率中均居首位。一半以上的韩国肺癌患者接受化疗,包括辅助治疗。化疗中根据活检和基因检测结果使用细胞毒药物、靶向治疗和免疫检查点抑制剂。在化疗中,发展较快的是靶向治疗。美国国立综合癌症网络(NCCN)指南最近更新了针对多基因突变的靶向治疗,靶向治疗不仅用于化疗,也用于辅助治疗。以前的靶向疗法是针对常见的基因突变而开发的,而最近开发的靶向疗法则是为了克服不常见的基因突变或以前的靶向疗法后出现的耐药性。因此,本研究介绍了近期快速发展的靶向疗法。
{"title":"New Targeted Therapy for Non-Small Cell Lung Cancer.","authors":"Eun Ki Chung, Seung Hyun Yong, Eun Hye Lee, Eun Young Kim, Yoon Soo Chang, Sang Hoon Lee","doi":"10.4046/trd.2022.0066","DOIUrl":"10.4046/trd.2022.0066","url":null,"abstract":"<p><p>Lung cancer ranks first in cancer mortality in Korea and cancer incidence in Korean men. More than half of Korean lung cancer patients undergo chemotherapy, including adjuvant therapy. Cytotoxic agents, targeted therapy, and immune checkpoint inhibitors are used in chemotherapy according to the biopsy and genetic test results. Among chemotherapy, the one that has developed rapidly is targeted therapy. The National Comprehensive Cancer Network (NCCN) guidelines have been updated recently for targeted therapy of multiple gene mutations, and targeted therapy is used not only for chemotherapy but also for adjuvant therapy. While previously targeted therapies have been developed for common genetic mutations, recently targeted therapies have been developed to overcome uncommon mutations or drug resistance that have occurred since previous targeted therapy. Therefore, this study describes recent, rapidly developing targeted therapies.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":"86 1","pages":"1-13"},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ab/c9/trd-2022-0066.PMC9816494.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10522204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Captive. 俘虏。
IF 2.9 Q2 RESPIRATORY SYSTEM Pub Date : 2023-01-01 DOI: 10.4046/trd.2022.0130
Brian Robert Smith
{"title":"Captive.","authors":"Brian Robert Smith","doi":"10.4046/trd.2022.0130","DOIUrl":"https://doi.org/10.4046/trd.2022.0130","url":null,"abstract":"","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":"86 1","pages":"57-58"},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/22/2c/trd-2022-0130.PMC9816491.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10867769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Tuberculosis and Respiratory Diseases
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1